Author

Michelle Ugolini Lopes

Observed names: M Ugolini Lopes, M. Ugolini Lopes

Institution: Eli Lilly (United States)

Observed institution: Eli Lilly (United States)

OpenAlex ID: A5111350222

OP35 Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate to severe Crohn’s disease: Results from the phase 3 VIVID 1 study

2024 · V Jairath, B E Sands, et al. · Journal of Crohn s and Colitis · 26

DOP046 Effectiveness and Safety of Mirikizumab after switching from Ustekinumab in patients with moderate to severe Crohn’s disease: results from a long-term extension study

2025 · G D'Haens, D Laharie, et al. · Journal of Crohn s and Colitis · 2

P12 Early symptomatic improvement with mirikizumab induction therapy in patients with moderately-to-severely active crohn’s disease: phase 3 vivid-1 study results

2025 · Bruce E Sands, Min-Hu Chen, et al.

Efficacy of mirikizumab in patients with moderate-to-severe Crohn’s disease in comparison to ustekinumab: Summary results from the double-blind Phase 3 VIVID-1 trial

2024 · S. Zeissig, M. Ferrante, et al. · Zeitschrift für Gastroenterologie

P116 Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s disease: results of the treat-through VIVID 1 study

2024 · Marc Ferrante, Silvio Danese, et al. · Poster presentations

Works count: 5

Citation count: 28

H-index: 2

I10-index: 1